Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zamicastat - Bial

Drug Profile

Zamicastat - Bial

Alternative Names: BIA-5-1058

Latest Information Update: 13 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bial
  • Developer BIAL
  • Class Antihypertensives; Chromans; Heart failure therapies; Imidazoles; Small molecules; Thiones
  • Mechanism of Action Dopamine beta hydroxylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pulmonary arterial hypertension
  • Phase I Heart failure

Most Recent Events

  • 23 Aug 2019 Bial initiates completes enrolment in a phase I trial in healthy volunteers in United Kingdom before August 2019(NCT04069130)
  • 08 Apr 2019 Bial initiates a phase I trial in healthy volunteers in United Kingdom (NCT04069130)
  • 20 Dec 2018 Phase-II clinical trials in Pulmonary arterial hypertension (Adjuvant therapy) in Austria (PO) (EudraCT2018-002796-18 )
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top